In contrast to neurofilaments and genetic modifiers, SMN protein and SMN-mRNA appear to be promising predictive and pharmacodynamic biomarkers for systemic treatments in both pediatric and adult SMA patients (55). The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.